InspireMD to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021, and Provide Corporate Update
August 04 2021 - 8:30AM
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic
Prevention Stent System (EPS) device for the treatment of Carotid
Artery Disease (CAD) and stroke prevention, today announces it will
report fiscal first quarter 2021 financial results on Tuesday,
August 10, 2021, before the market opens. Management will host a
conference call on Tuesday, August 10, at 8:30 a.m. ET to review
financial results and provide an update on corporate developments.
Following management’s formal remarks, there will be a
question-and-answer session. Participants are asked to pre-register
for the call through the following link:
https://dpregister.com/sreg/10158721/eb2ec48868.
Please note that registered participants will receive their dial
in number upon registration and will dial directly into the call
without delay. Those without internet access or unable to
pre-register may dial in by calling: 1-844-854-4417 (domestic), or
1-412-317-5739 (international). All callers should dial in
approximately 10 minutes prior to the scheduled start time and ask
to be joined into the InspireMD call.
The conference call will also be available through a live
webcast found
here:https://services.choruscall.com/mediaframe/webcast.html?webcastid=a2t5MXpf.
Additionally, it will be broadcast live through the Company’s
website via the following
link:https://www.inspiremd.com/en/investors/investor-relations/.
A webcast replay of the call will be available approximately one
hour after the end of the call through November 10, 2021, at the
above links. A telephonic replay of the call will be available
through August 24, 2021 and may be accessed by calling
1-877-344-7529 (domestic) or 1-412-317-0088 (international) and
using access code 10158721.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology
to make its products the industry standard for carotid stenting by
providing outstanding acute results and durable, stroke-free,
long-term outcomes.
Forward-looking Statements
This press release contains “forward-looking
statements.” Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. For example, the Company is using
forward-looking statements when it discusses the number of expected
patients to be enrolled in the trial, that the initiation of the
trial marks an important milestone for the potential approval of
the CGuard EPS and towards advancing the treatment of CAD and
stroke prevention, and that the initiation of the trial marks the
beginning of the next step in the Company’s journey towards CGuard
EPS being utilized in the U.S. Forward-looking statements are not
guarantees of future performance, are based on certain assumptions
and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company’s control, and
cannot be predicted or quantified and consequently, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include,
without limitation, risks and uncertainties associated with (i)
market acceptance of our existing and new products, (ii) negative
clinical trial results or lengthy product delays in key markets,
(iii) an inability to secure regulatory approvals for the sale of
our products, (iv) intense competition in the medical device
industry from much larger, multinational companies, (v) product
liability claims, (vi) product malfunctions, (vii) our limited
manufacturing capabilities and reliance on subcontractors for
assistance, (viii) insufficient or inadequate reimbursement by
governmental and other third party payers for our products, (ix)
our efforts to successfully obtain and maintain intellectual
property protection covering our products, which may not be
successful, (x) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (xi) our
reliance on single suppliers for certain product components, (xii)
the fact that we will need to raise additional capital to meet our
business requirements in the future and that such capital raising
may be costly, dilutive or difficult to obtain and (xiii) the fact
that we conduct business in multiple foreign jurisdictions,
exposing us to foreign currency exchange rate fluctuations,
logistical and communications challenges, burdens and costs of
compliance with foreign laws and political and economic instability
in each jurisdiction. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s web site at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Investor Contacts:
Craig ShoreChief Financial OfficerInspireMD,
Inc.888-776-6804craigs@inspiremd.com
CORE IRinvestor-relations@inspiremd.com
InspireMD (NASDAQ:NSPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
InspireMD (NASDAQ:NSPR)
Historical Stock Chart
From Apr 2023 to Apr 2024